ChemicalBook Product Catalog Biochemical Engineering Polypeptide Survodutide

Survodutide

Product NameSurvodutide
CAS2805997-46-8
MF
MW0
EINECS997-146-8
MOL FileMol File

Chemical Properties

solubility	PBS (pH 7.2): Soluble: =10 mg/ml
form	Solid
color	White to off-white

Usage And Synthesis

Uses

Survodutide is a dual glucagon/glucagon-like peptide 1 (GLP1) receptor agonist. Survodutide has demonstrated blood sugar lowering efficacy in a Phase II trial for the treatment of patients with type 2 diabetes and obesity and was associated with clinically meaningful weight loss^[1]. Survodutide is also being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)^[2].

in vivo

Survodutide (BI 456906; 3, 10, 20, 30 nmol/kg; SC; daily; 30 days) achieves a greater bodyweight-lowering efficacy in diet-induced obese mice compared with maximally effective doses of Semaglutide (HY-114118; 20, 100 nmol/kg). Survodutide dose-dependently reduces plasma glucagon^[1].
Survodutide (1, 3, 10, 30, 100 nmol/kg; SC; single dose) dose-dependently reducesacute food intake in WT but not in GLP-1R KO mice (Three-week-old, male, lean NMRI outbred mice)^[1].
Survodutide (1, 3, 10, 30, 100 nmol/kg; SC; single dose) engages the glucagon receptor in vivo upon single dosing, increases liver nicotinamide N-methyltransferase mRNA, and reduces plasma serine and glutamine^[1].
Survodutide (SC injection) causes mean residence times of 44 and 140 h and T_max values of 7 and 51 h obtained in mice and dogs, respectively^[1].
Pharmacokinetic Parameters of Survodutide (BI 456906) in mice and dogs^[1].

	Mice (20 nmol/kg; SC)	Dogs (10 nmol/kg; SC)
T_max (h)	7	50.7
C_max (nM)	84.9	62.0
AUC_0-∞ (nMh)	4640	9540

Animal Model:	Male C57BL6/J mice pre-fed with a 60% HFD (22 weeks)^[1]
Dosage:	3, 10, 20, 30 nmol/kg
Administration:	SC; daily; 30 days
Result:	Dose-dependently reduced bodyweight from baseline by up to 32% at Day 28 at a dose of 30 nmol/kg.

References

[1] BRIAND F, AUGUSTIN R, WESCHE F, et al. 1635-P: Survodutide Weight Loss Is Associated with Changes in Food Preference and Improvement of Dyslipidemia in the Free Choice Diet–Induced Obese Hamster Model[J]. Diabetes, 2024, 33 2. DOI:10.2337/db24-1635-p.
[2] Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis[J]. Journal of Hepatology, 2024, 81 5: Pages 837-846. DOI:10.1016/j.jhep.2024.06.003.
[3] TINA ZIMMERMANN . BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy[J]. Molecular Metabolism, 2022, 66: Article 101633. DOI: 10.1016/j.molmet.2022.101633

Survodutide Supplier

Survodutide manufacturers

Related Product Information

Send Inquriy